Neurosphere involved in a new project with Neurasic Therapeutics, CQDM and Louise and Alan Edwards Foundation
NeuroSphere is pleased to continue to support Neurasic Therapeutics and Dr. Philippe Séguéla since our involvement in the launch of Neurasic therapeutics in 2020 and announce a new $965,000 collaboration between Neurasic Therapeutics, CQDM, the Louise and Alan Edwards Foundation, and Neurosphere. This collaborative research project has the potential to make progress towards the development of a new class of analgesics designed to combat refractory pain without the side effects of opioids.
This new project is lead by Philippe Séguéla, a pioneer in the identification of pain channel genes and non-opioid analgesic mechanisms, at the Neuro (Montreal Neurological Institute-Hospital). The project is made possible through CQDM innovation funding and a contribution of $200,000 from HBHL.
“Through its Neuro-Partnerships Program, HBHL is proud to help fund this new project in collaboration with CQDM and other industry partners," said Xavier Linker, Associate Director of Business Development at HBHL. "As this project aims to provide new opiate-sparing pain-relieving drugs, it aligns perfectly with HBHL’s vision to improve the quality of life of Canadians and people around the world. Furthermore, funding this project builds on the previous work done by NeuroSphere, McGill’s neuroscience accelerator funded through HBHL, to help start Neurasic Therapeutics.”